Direct oral anticoagulants (DOACs) are commonly used oral factor Xa inhibitors in recent
years. However, in some special clinical situations, the appropriate use of these …

BACKGROUND: Direct-acting oral anticoagulants (DOACs) represent an alternative to
vitamin K antagonists in the treatment of venous thromboembolism (VTE); however …

The risk of a venous thromboembolic event is not limited to the pre-hospital, hospital, or
immediate post-hospital period. Because of challenges with data collection, the risk of …

ABSTRACT Objectives Direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban,
commonly used direct oral anticoagulant (DOAC), are widely used to prevent and treat …

The major practical advantage of the direct oral anticoagulants (DOACs), comprising the
thrombin inhibitor dabigatran and the factor Xa inhibitors apixaban, edoxaban, and …

The last decade has seen the evaluation of several new oral anticoagulants that directly
target thrombin or activated factor X (FXa). All demonstrate a rapid onset of action, a low …

Four direct oral anticoagulants (DOACs)—dabigatran, a direct thrombin inhibitor, and the
direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban—have been approved for …

Thrombosis is a leading cause of morbidity and mortality in the United States. Arterial and
venous thromboses are implicated in the pathogenesis of major disorders, including …

Use of direct oral anticoagulants (DOACs), particularly the direct factor Xa inhibitors,
rivaroxaban and apixaban, as prophylaxis for venous thromboembolism (VTE)[1, 2] and/or …

Direct oral anticoagulants (DOACs) have largely replaced vitamin K antagonists, mostly
warfarin, for the main indications for oral anticoagulation, prevention and treatment of …